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Extracellular vesicles (EVs) are membrane-surrounded structures released by most cell
types. They are characterized by a specific set of proteins, lipids and nucleic acids.
EVs have been recognized as potent vehicles of intercellular communication to transmit
biological signals between cells. In addition, pathophysiological roles of EVs in conditions
like cancer, infectious diseases and neurodegenerative disorders are well established.
In recent years focus has been shifted on therapeutic use of stem cell derived-EVs.
Use of stem cell derived-EVs present distinct advantage over the whole stem cells as
EVs do not replicate and after intravenous administration, they are less likely to trap
inside the lungs. From the therapeutic perspective, the most promising cellular sources
of EVs are mesenchymal stem cells (MSCs), which are easy to obtain and maintain.
Therapeutic activity of MSCs has been shown in numerous animal models and the
beneficial paracrine effect of MSCs may be mediated by EVs. The various components
of MSC derived-EVs such as proteins, lipids, and RNA might play a specific therapeutic
role. In this review, we characterize the role of EVs in immune and central nervous system
(CNS); present evidences for defective signaling of these vesicles in neurodegeneration
and therapeutic role of EVs in CNS.
Keywords: extracellular vesicles, mesenchymal stromal cells, CNS, neurological diseases, biomarkers,
transplantation
INTRODUCTION
Mesenchymal stem/stromal cells (MSCs) are of great interest in regenerative therapy for tissues
damaged by various pathological conditions. The chief therapeutic attributes of MSCs are their
ability to migrate into injured sites (Kraitchman et al., 2005; Kim et al., 2015), promote functional
recovery and modulate immune responses. Although the process of MSC homing is not very
effective and there were various strategies attempted to enhance it. The engineering of MSC
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facilitates reaching target organs (Nowakowski et al., 2016).
Another approaches are based on more direct routes of cell
delivery, which, however, are slightly more invasive. After finding
conditions determining the safety of intra-arterial delivery
(Janowski et al., 2013; Cui et al., 2015), this route has been
found effective in animal model of stroke (Toyoshima et al.,
2015). The intrathecal route is even less invasive and was
also shown effective (Lim et al., 2011). The intracerebral
route is more invasive and is going to be used rather as
an addition to neurosurgical treatment such as evacuation of
hematoma (Zhang Q. et al., 2015). In general, it was thought
that the close proximity of transplanted MSCs is pivotal in
achievement of substantial therapeutic effect, as the cells could
act through various mechanisms such as direct cell-to-cell
contact and secreted factors. However, an extensive meta-
analysis of preclinical results of intravenous application of
stem cell revealed that there is a good correlation between
a dose of infused cells and therapeutic effect, however, such
correlation does not exist between the outcome and number of
cells that engrafted within the disordered brain area (Janowski
et al., 2010). It indicates that, there are substantial therapeutic
mechanisms that are not directly related to the presence of cells
within the injury site. Additional, accumulating evidence over
the past few years supports the notion that the predominant
mechanism by which MSCs act in tissue repair is mainly
related to their paracrine/secretory effect. Indeed, MSCs provide
microenvironment with a multitude of trophic signals including
growth factors and cytokines. It is likely that in parallel to
soluble factors, MSCs release EVs that contribute to the reparative
process by intercellular cross talk communication. The biological
relevance of extracellular vesicles (EVs) that mirrors parental cells
has been established in different experimental settings. Recent
discoveries suggest that they have similar protective properties
as their cellular counterparts to condition and reprogram
the surrounding microenvironment influencing a variety of
endogenous responses in particular in injured tissues. It has
been shown that EVs can affect other cells via transfer of
genetic cargo, transfer of receptors and ultimately initiating
pathways (Momen-Heravi et al., 2013). They are able to modify
cell fate, function and plasticity. Recent data indicate that
EVs have the capacity to modulate immune response and
facilitate tissue regeneration. Therefore the use of them may
represent an interesting alternative therapy for various diseases
compared to a cell-based approach. EVs released by MSCs are
heterogeneous population that differs in size and biogenesis.
They contain proteins, bioactive lipids and nucleic acids that can
mediate various signaling functions contributing to homeostasis.
Transfer of these molecules to neighboring cells promotes cell-
to-cell communication and modifies the activity of target cells.
In the central nervous system (CNS) probably more than in
other organs such communication between neurons and glial
cells is very crucial in physiological conditions. There is also
strong evidence that EVs play a role in learning and memory
(Smalheiser, 2007). Moreover, the biomolecules delivered by
these structures may support and protect neurons, remove
debris and infectious agents as well as control inflammation in
pathological situation. They are involved in removal of misfolded
proteins, harmful cell metabolic products and viral particles
(Inal et al., 2012; Ohno et al., 2013). The recent literature
implicates that microvesicles have the potential to transfer a
collection of biomolecules between cells locally or over long
distance through the blood or other biological fluids (Baglio
et al., 2012; Frühbeis et al., 2013; Raposo and Stoorvogel,
2013). The circulation half-life of EVs in blood is approximately
2 min (Takahashi et al., 2013; Saunderson et al., 2014) but they
have been detected in lungs, liver, spleen, and pancreas 48 h
after systemic injection (Wiklander et al., 2015). This opens
novel therapeutic perspectives aimed at the development of
cell-free strategies based on the use of MSCs secretome as a
potentially more advantageous alternative to cell-based therapy
approaches.
In this review we summarize role of EVs in pathophysiology of
different neurological and immunological conations, properties
and functions of EVs derived from MSCs and their potential
therapeutic role in neurological disorders.
TYPES AND PRODUCTION OF EVs
Extracellular vesicles can be categorized into three main classes
based on their mode of origin: exosomes, shedding microvesicles
and apoptotic bodies (Figure 1). In broad terms there are
three types of EVs, however, in the literature the nomenclature
is inconsistent and the term microvesicles is often used
as an umbrella term to encompass exosomes and shedding
microvesicles (Lai et al., 2015).
Exosomes represent a specific subtype of secreted vesicles.
They are presently the best-characterized species of EVs.
Exosomes arise in the endocytic pathway and are released by
exocytosis through a mechanism dependent on cytoskeleton
activation regulated by p53 protein but independently of
cell calcium influx (Tetta et al., 2011; Biancone et al.,
2012). They are small spherical vesicles with a size of 30–
120 nm, cup shaped, limited by lipid bilayer, and constituted
a rather homogenous population. Exosomes are derived from
late endocytic compartments, known as multivesicular bodies
(MVBs). They are produced by inward invagination of
endosomal membranes to form MVBs, which subsequently fuse
with the plasma membrane and release their intraluminal vesicles
as exosomes to the extracellular milieu (Lai and Breakefield,
2012). As endocytosis is most active at specific unique micro
domains in the plasma membrane called lipid rafts, exosomes
have membranes enriched in elements of lipid rafts such as
GM1 gangliosides and transferrin receptors (Tan et al., 2013).
They are rich in annexins, tetraspanins (CD63, CD81, and CD9)
and heat shock proteins (Hsp60, Hsp70, and Hsp90), expose
clathrin, calveolins as well as endosome-specific proteins such
as Alix and Tsg101 and cell-type specific proteins (Biancone
et al., 2012; Frühbeis et al., 2013; Sabin and Kikyo, 2014).
Exosomes carry characteristic lipids and contain cholesterol,
ceramide, sphingomyelin, and phosphatidylserine (Subra et al.,
2007). As mentioned above, nucleic acids such as mRNA
and miRNA are also present in exosomes (Mathivanan et al.,
2010).
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FIGURE 1 | Different types of extracellular vesicles (EVs) released from parental cells.
Shedding vesicles known as ectosomes or microvesicles are
another class of EVs. As the name implies, they are shed
directly from the plasma membrane of the cell. Microvesicles
are heterogeneous in size, ranging from 100 nm to 1 µm. Their
release is initiated by outward budding from the membrane
surface followed by a fission event similar to the abscission
step observed in cytokinesis (Turturici et al., 2014). Shedding
of vesicles is physiological phenomenon that accompanied cell
activation and growth. Their detachment from small cytoplasmic
protrusions depends on calcium influx, calpain, scramblase,
floppase, and cytoskeleton reorganization (Cocucci et al., 2009;
Tetta et al., 2011). Calcium ions are responsible for the
changes in asymetric phospholipid distribution of the plasma
membrane that lead to the formation of shedding vesicles
(Biancone et al., 2012). The release of microvesicles occurs
from all types of cells in resting state, or upon activation
by soluble factors or oxidative stress, hypoxia or shear stress.
However, the main function of shedding vesicles is signaling
through specific interaction with target cells and the transfer
of genetic information (mRNA). Microvesicles influence the
behavior of target cells in multiple ways, such as signaling
complexes by direct stimulation, transferring receptors between
cells or delivering proteins. Microvesicles may transmit miRNA
to neighboring cells that can alter the expression of genes
in these cells. The content of microvesicles differs to some
extent from that of exosomes. Shedding vesicles lack proteins
of the endocytic pathway but they expose high amounts
of phosphatidylserine, contain protein associated with lipid
rafts such as integrins and flotillins and are enriched in
cholesterol, sphingomyelin, and ceramide (Mathivanan et al.,
2010). Although tetraspanins are considered as unique markers
for exosomes, they can be expressed in shedding microvesicles in
some cases.
Apoptotic bodies represent another type of EVs. Although
they resemble microvesicles they can be distinguished by their
large size and irregular shape (György et al., 2011). In contrast
to exosomes and microvesicles that derive from healthy cells,
apoptotic bodies are released during the apoptosis. They are
formed during the late stage of apoptosis and contain nuclear
material, cellular organelles and membrane contents. They
express phosphatidylserine on their surface and have a permeable
membrane (Turturici et al., 2014). Apoptotic bodies tend to elicit
an anti-inflammatory or tolerogenic response when taken up by
neighboring cells (Lai et al., 2015; Table 1).
PROTEOMIC ANALYSIS OF MSC-EVs
Extracellular vesicles are composed of various molecules
including proteins, lipids, and nucleic acids. Secreted proteins
participate in intercellular communication and play a role in
cell signaling, differentiation, cell adhesion, angiogenesis, and
apoptosis. A variety of cytokines, chemokines, growth factors,
extracellular matrix (ECM) proteins and remodeling enzymes
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TABLE 1 | The properties of different types of extracellular vesicles (EVs).
Property Exosomes Microvesicles Apoptotic bodies
Size 30–120 nm 100–1000 nm 50–4000 nm
Morphology Homogenous cup-shape Heterogeneous irregular Heterogeneous irregular
Buoyant density 1,13–1,19 g/cm3 Not well defined 1,16–1,28 g/cm3
Origin Endosomal Plasma membrane Apoptotic cells
Proteins CD63, CD81, CD9, annexins, heat-shock
proteins, Alix, Tsg101, clathrin, caveolins,
integrins, TfRs
Integrins, flotillins, selectins, CD40,
metalloproteinases
Histones
Lipids Lysobisphosphatidic acid, cholesterol,
ceramide, sphingomyelin and low concentration
of phosphatidylserine
High amount of cholesterol, sphingomyelin,
ceramide, high concentration of
phosphatidylserine
High concentration of
phosphatidylserine
Nucleic acids mRNA and miRNA mRNA and miRNA mRNA, miRNA, fragments of DNA
have been identified in MSCs derived from different sources and
their secretomes (Kupcova Skalnikova, 2013).
The initial proteomic characterization of EVs secreted
from MSCs was published by Kim et al. (2012) and Lai
et al. (2012). Kim et al. (2012) using mass spectrometry
profiled the proteome of microvesicles (in size from 50 to
200 nm) which were harvested by ultracentrifugation from
human bone marrow MSCs and identified 730 proteins.
Lai et al. (2012) distinguished 857 proteins with the same
technique in exosomes isolated from human ESC-derived
mesenchymal stem cells (MSCs; huES9.E1) line by high
performance liquid chromatography. In these two articles we
can find a common subset of 315 proteins (Supplementary
Tables S1 and S2). Among the sets of proteins, in addition
to cytoplasmic proteins a remarkable number of membrane
proteins have been found. The proteins located in the plasma
membrane and cytoplasm are more commonly sorted into EVs
compared with the proteins in the nucleus and mitochondria
of different cell types (Yoon et al., 2014). Specific markers
of MSCs, i.e., CD9, CD63, CD81, CD109, CD151, CD248,
and CD276 as well as surface receptors (PDGF-RB, EGF-
R, and PLAUR) involve in tissue recruitment and signaling
molecules (RRAS/NRAS, Wnt5B, MAPK1, GNA13/GNG12,
RHO, CDC42, and VAV2) controlling self-renewal and cell
differentiation of human BM- MSCs have been reported
(Kim et al., 2012). Consistent with the previous finding
that EVs proteome include the proteins associated with EVs
biogenesis and trafficking. Proteins implicated in intracellular
transport and fusion, i.e., RAB are also very often present
in EVs (Kowal et al., 2014, review). RAB proteins are
accompanied with granule secretion, Golgi apparatus transport,
tight junctions formation and ligand sequestration at the
plasma membrane. These proteins, i.e., RAB1A, RAB2A,
RAB5A/B/C, RAB7A, and RAB8A regulate docking and fusion
of MVs with the recipient cell as well as proper targeting of
them to various cellular compartments. Functional properties
are also represented by proteins engaged in BM-MSCs-MVs
cell adhesion (FN1, E2R, IQGAP1, CD47, LGALs1/LGALS3,
and integrins), migration, and morphogenesis (Kim et al.,
2012).
Lai et al. (2012) detected many important groups of peptides,
i.e., ACTA, Alix, ANX, HSP, TUB, and TWHA that are
secreted in the regular manner and be present in MVs derived
from human ESC-MSCs. Some of these molecules were also
characterized by Thery et al. (2009) in MVs derived from
immune cells. Among them tetraspanins, clathrin, annexins,
GAPDh, PK, EEF1A1, MFGES, MHC class I, cofilin1, ezrin,
radixin, moesin, actin, and tubulin found in at least 50% of
all examined exosomes (Thery et al., 2009). Nowadays, there
are two public databases: EVpedia and ExoCarta containing
data of EVs components of different cell types from several
studies (Mathivanan et al., 2012; Choi et al., 2013). Similar to
exosomes from other sources, protein components in MSC-
derived exosomes do not remain constant due to heterogeneity
of MSCs. Moreover, variations in the cell preparation have an
influence on secretome profile of MSC derived from different
sources (Lavoie and Rosu-Myles, 2013). The differences in
protein content have been also detected in various batches of
MSC-EVs (Yu et al., 2014). The proteomic analysis of EVs
derived from MSCs isolated from different sources reveals
distinguishing features from EVs derived from other types
of cells (Skalnikova et al., 2011) and among microvesicles
originated from MSCs of varying sources. Only a few studies
have identified the whole proteome contained in MSC-derived
EVs (Kim et al., 2012; Lai et al., 2012). However, the functional
differences between EVs originated from distinct MSC sources
clearly indicate the existence of difference in their composition.
In both, in vitro dorsal root ganglia neurons and cortical
neuron cultures cells react differentially to treatment with bone
narrow (BM), umbilical cord blood (UCB), chorion (Cho-
SC) and human menstrual fluid (MenSC) MSCs derived-
exosomes. From all mentioned vesicles only MenSC -exosomes
are able to enhance neurit outgrowth in cortical neuron
cultures, while Cho-SC-exosomes cause even decrease of total
neuron branch number. Moreover BM- and MenSC-derived
exosomes increased the rate of neuritic growth in dorsal
root ganglia neurons culture in comparison to control cells
(Lopez-Verrilli et al., 2016). Similar observations were made
in case of glioblastoma research. Among microvesicles (MVs)
acquired from BM, UCB, and adipose tissue (AT) MSC only
BM- and UCB-derived MVs decreased proliferation rate of
glioblastoma cells line, whereas AT-MSC MVs had opposite
effect. Induction of neoplasm cells apoptosis was observed
after treatment with microvesicles from BM and UCB-MSC
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with no result in case of AT-MSC MVs (Del Fattore et al.,
2015b). Furthermore these functional differences have been
demonstrated even between vesicles from the same source
but belonging to other sub-populations. Exosome-enriched
fraction derived from BM-MSCs enhanced neurite outgrowth
whereas the microvesicle-enriched fraction showed inhibitory
effect (Lopez-Verrilli et al., 2016). The realization of more
comparative studies between EVs derived from MSC from
different sources is required. Based on these data it appears that
MSC-EVs hold many characteristics of the MSCs themselves.
Interestingly metalloproteinase inhibitors TIMP-1 and TIMP-2
were expressed only in human BM-MSC-EVs but not in parental
cells (Vallabhaneni et al., 2015). In literature we can find a
few examples of proteins which were present in microvesicles
although they were not detected in cells of their origin. Authors
of these articles associate this phenomenon with existence
of very precise proteins sorting system during microvesicles
biogenesis or limitation of protein identification techniques
(Table 2) which very often suffer from high detection threshold or
necessity of normalization of obtained results to the total protein
level.
LIPIDOMIC ANALYSIS OF EVs
Except proteins EVs contain bioactive lipids. As for proteins,
the lipid composition in EVs is distinct from that of the cell
origin. Internal membranes of EVs isolated from different cell
types are enriched in lysobisphosphatidic acids that modulate
budding process and lipids associated with lipid rafts such as
cholesterol, ceramide, sphingolipids, and glycerophospholipids
with saturated fatty-acyl chains (Urbanelli et al., 2015).
Sphingomyelin and cholesterol allow the tight packing of lipid
bilayers and increase rigidity and stability of EVs derived from
different cells, prevent their recognition by blood components
and uptake, facilitate the fusion of EVs (Yoon et al., 2014).
EVs also contain many lipid mediators such as prostaglandins
and enzymes involved in their synthesis from membrane
phospholipids. Subra et al have shown the presence of a set
of phospholipases (A2, C, and D) in EVs isolated from RBL-
2H3 cells. Also a large panel of free fatty acids including
arachidonic acid were detected in EVs from mast cells (Subra
et al., 2010).
PROFILING RNA CONTENT IN EVs
The RNA cargo has been well established as a component of
EVs isolated from different cell types (Ratajczak et al., 2006).
Various RNA species have been detected within EVs. The micro
RNA (miRNA) is most abundant RNA species in human plasma
and makeup over 76% of all mappable reads (Huang et al.,
2013). Detailed analysis has shown that actually not mature
miRNA but precursor miRNA (pre-miRNA) is mostly present
in exosomes isolated from ESC-MSCs (Chen et al., 2013).
There were found profound discrepancies between the exosomal
and cellular content of miRNA suggesting an active process
of sorting and packaging of miRNA into exosomes (Zhang J.
et al., 2015). MSC-derived exosomes also contain significant
amount of transfer RNA (tRNA), with striking differences in
content between cells of AT or bone marrow origin, while no
difference in miRNA content between these two cell sources
has been found (Baglio et al., 2015). This may account for
the differences observed between them (Muhammad et al.,
2015). The translatable and fragmented mRNA is also present
in EVs from different biological fluids (Rani et al., 2011).
The RNA content varies depending of the exosome origin,
for instance the fragments of ribosomal RNA (rRNA) was the
most abundant RNA species found in breast cancer-derived
EVs (Jenjaroenpun et al., 2013). The piwi-interacting RNA
(piRNA) has been also recently detected in exosomes isolated
from human saliva (Ogawa et al., 2013). It was recently found
that EVs may not only cargo RNA, but also process it. Such
process was observed in cancer-derived EVs and processed
RNA was toxic for primary human cells (Chakrabortty et al.,
2015). The high interest in RNA cargo of exosomes takes
advantage of new methods of RNA isolation, which may bring
more detailed characterization in near future (Enderle et al.,
2015).
MECHANISM OF CELLULAR UPTAKE OF
EVs
Extracellular vesicles released from parental cells may be broken
down, thus releasing their content into extracellular space or
neighbor cells may internalize them. The pathways through
which EVs enter target cells impact EV-mediated biomolecule
delivery. Several types of interactions between EVs and target
cells have been demonstrated. Interaction may be direct,
resulting in MVs fusion or endocytosis, i.e., observed between
mouse dendritic cells ( (Mathivanan et al., 2010; Montecalvo
et al., 2012) or indirect, by binding to surface receptors as
visualized between tumor and immune cells (Clayton and
Mason, 2009; Pan et al., 2014). EVs uptake is initiated by
specific receptor-ligand interaction. The receptor-ligand binding
is determined by several molecules such as integrins, tetraspanins
and galectins and other adhesion molecules present on EVs
isolated from different cell types and cell surface. (Rana et al.,
2011; Raposo and Stoorvogel, 2013). The pattern of their
expression is consistent with that of the cell origin. The
correct orientation of these receptors enables their capability
of encountering multiple ligands after their secretion from the
cell (Morel et al., 2004). The presence of β1 and β2 integrins
on exosomes of various cellular sources was shown. Clayton
et al demonstrated that exosome integrins derived from B
cells are capable of interactions with surrounding ECM and
adhere to the ECM components such as collagen and fibronectin
(Clayton et al., 2004). These adhesive interactions may limit
diffusion of exosomes from the site of secretion. In inflammation
or tissue injury, disruption of ECM leads to release ECM-
bound exosomes liberating them to interact with resident or
inflammatory cells expressing up-regulated adhesion molecules,
i.e., ICAM-1, LFA-1, TIM-1, or TIM-4 (Thery et al., 2009). EVs
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TABLE 2 | Examples of articles with identification of differences between proteins composition in cells and vesicles originated from them.
Protein EVs type Differentiating feature Authors’ explanation,
comment
Reference
Type Cells of origin Derived EVs
NEP ADSC-derived
exosomes
Enzymatic
activity
∼40% of total activity ∼90% of total
activity
Unknown reason, it is likely that
NEP was enriched in exosomes
during their biogenesis
Katsuda
et al., 2013
NEP BM-MSC-
derived
exosomes
Enzymatic
activity
weak/undetectable 70% of total activity
CD63 ADSC-derived
exosomes
Concentration Higher Weaker CD63, CD81 are the
well-established exosomal
markers; Cyt-c and actin are
typical cellular proteins
CD81 Weak/undetectable Present
Cyt-c Present Weak/undetectable
Actin Present Weak/undetectable
LAMP2
CD90
PDGFR-β
CD9
CD81
TIMP-1
TIMP-2
BM-MSC
vesicular
fraction
40–150 nm
Concentration Weaker
Weaker
Higher
Weak/undetectable
Weak/undetectable
Weak/undetectable
Weak/undetectable
Higher
Higher
Weaker
Present
Present
Present
Present
Results indicate the existence
of regulated packaging
mechanism of EVs with
proteins that may not be highly
expressed in cells; This
research were done using
western blot technique in which
result is normalized to the same
amount of total protein, the
data seen is function of ratio of
specific protein to total number
of proteins
Vallabhaneni
et al., 2015
Galectin-1 BM-MSC
microvesicles
Concentration Higher Weaker Typical microvesicles
characteristic
Kim et al.,
2012HSP90 Higher Weaker
CD63 Higher Weaker
β-actin Higher Weaker
CD63 MenSC
microvesicles
Concentration Weaker Higher The non-exosomal protein
Rab5 was not detected
Lopez-Verrilli
et al., 2016TSG101 Weaker Higher
Hsp70 Weaker Higher
Hsp90 Weaker Higher
Rab5 Present Weak/undetectable
may also potentiate ECM digestion through their inclusion or
activation of matrix metalloproteinases (MMPs) such as MMP-
2 and MMP-9 (Candela et al., 2010). Some studies revealed
that EVs derived from platelet contained cytokine receptors
(TNF-RI, and TNR-RII), platelet endothelium receptors (CD41,
CD61, and CD62) and special ligands (CD40L, and PF-4)
which could be transported into the target cells and enable
platelet adhesion (Baj-Krzyworzeka et al., 2002). Furthermore,
platelet derived EVs are able to interact with monocytes and
endothelial cells but not with neutrophils. (Lösche et al.,
2004) whereas EVs derived from neutrophils interfere with
endothelial cells, monocytes and dendritic cells (DCs; Gasser
et al., 2003; Eken et al., 2008). Once attached onto plasma
membrane EVs moved in a slow drifted mode, then the
motion mode changed to a rapid directed mode, indicating
that EVs internalization occurred (Tian et al., 2013). After
cellular uptake EVs are segregated within endosomes and fuse
with lysosomes for degradation or with endosome membranes
thus releasing their cargo into the cytoplasm (Turturici et al.,
2014). Other studies revealed the evidence for accumulation of
EVs in phagocytic or endocytic compartments and suggest that
EVs uptake depends on the actin cytoskeleton, dynamin-2 and
phosphatidylinositol 3 kinase activity (Raposo and Stoorvogel,
2013).
BIOLOGICAL ACTIVITIES OF EVs
A very large collection of evidence shows that EVs are
important regulators of many biological functions such as tissue
homeostasis and immune response. EVs may influence the
behavior of target cells by several different mechanisms. First
they may act as signaling complexes. Indeed, EVs express several
surface molecules, i.e., ICAM-1 interacting with the specific
receptors LFA-1 present on T cells or δ-like 4 ligand bound
to Notch receptors expressed by endothelial cells and neuronal
cells thus activating these cells (Nolte-‘t Hoen et al., 2009;
Biancone et al., 2012). EVs play an important role in signaling
and morphogenesis during development. It was demonstrated
that certain morphogenes, i.e., sonic hedgehog or retinoic acid
associated with the epithelial cell membrane were released via
vesicles in response to FGF signaling (Greco et al., 2001).
Extracellular vesicles may also transfer receptors, proteins, or
bioactive lipids between cells after fusion with the target cell
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membrane. For example, the chemokine receptor CXCR4 or
CCR5 could be transferred from lymphocytes to nonlymphoid
cells (Rozmyslowicz et al., 2003). EVs-mediated transfer has
been also described for adhesion molecules between platelets
and hematopoietic cells (Baj-Krzyworzeka et al., 2002). Another
biological activity of EVs is connected with delivering proteins
to target cells. EVs may modulate the function of target cells by
transferring intracellular proteins. By convey of pro-angiogenic
factors, i.e., platelet-derived growth factor (PDGF), vascular
endothelial growth factor (VEGF), basic fibroblast growth factor
(BFGF) or leptin. EVs derived from CB-MSCs, BM-MSCs or
shed from tumor cells can activate angiogenesis (Taraboletti
et al., 2006; Zhang et al., 2012; Bian et al., 2014; Chen et al.,
2014). It has been shown that EVs derived from activated
monocytes are able to regulate apoptosis in target cells by
transferring caspase-1 (Sarkar et al., 2009). Similarly, EV-related
lipids induce several biological responses. The glycosphingolipids
present in intracerebrally administered exosomes bind to beta-
amyloid and clear the brain and decrease pathology in mouse
model of Alzheimer disease (Yuyama et al., 2014). However,
beta-amyloid induces the incorporation of C18 ceramides to
EVs produced in astrocytes, which in turn have pro-apoptotic
properties (Wang et al., 2012). In turn, the gangliosides GM1
and GM3 present in exosomes isolated from neuroblastoma
cells facilitate the aggregation of alpha-synuclein, a protein
involved in development of Parkinson disease (Grey et al., 2015).
The role of lipids was not specifically investigated in MSC-
derived EVs.
The miRNA mediates many biological effects through
inhibition of specific mRNA (Huang et al., 2015). For
example, miR-16 was capable to downregulate VEGF in
breast cancer cells (Lee et al., 2013). Human ESC-MSC-
derived exosomes are especially abundant with let-7 family
of miRNA, which through HNF4A suppression contribute to
maintenance of renewal of recipient stem cells (Koh et al.,
2010). It was shown that mRNA shuttled between cells is
functional and BM-MSC-derived exosomes transfer IGF-1R
mRNA based on which protein is produced (Tomasoni et al.,
2013). However, the most of mRNA present in exosomes is
highly fragmented and cannot serve as a template for protein
production, but it was found a very specific pattern of mRNA
fragmentation within exosomes with enrichment in the 3′-
intranslated regions. Since these regions are rich in miRNA
binding sites, exosomal mRNA can compete with intracellular
miRNA and disinhibit the mRNA translation (Batagov and
Kurochkin, 2013). No specific biological activity of piwi-
interacting RNA, tRNA, and rRNA present in exosomes has been
reported.
GENERAL CONSIDERATIONS ON THE
ROLE OF EVs IN THE FUNCTION OF
IMMUNE SYSTEM
Extracellular vesicles are involved both in promoting and in
inhibiting the immune response, depending on their cell of origin
and on the signals present in the microenvironment.
Macrophages infected by various pathogens (Mycobacterium
and Toxoplasma) release EVs containing pathogen-derived pro-
inflammatory molecular determinants inducing the secretion
of pro-inflammatory cytokines by recipient macrophages
(Bhatnagar and Schorey, 2007). Mycoplasma infection results
in the release of EVs inducing polyclonal activation of B and T
cells (Quah and O’Neill, 2007). EVs isolated from body fluids
could exacerbate autoimmune diseases. In Rheumatoid Arthritis
patients, fibroblasts isolated from synovial fluid secrete EVs
expressing TNFα, which promotes survival of T lymphocytes
(Zhang et al., 2006). EVs isolated from bronchoalveolar
fluid of patients with sarcoidosis stimulates the secretion of
pro-inflammatory cytokines by epithelial cells (Qazi et al., 2009).
Extracellular vesicles secreted by DCs can either promote or
inhibit immune response depending on the degree of maturation
of their parent cells. EVs produced by mature DCs carry
both antigenic material and MHC-peptide complexes required
for the initiation of immune responses by APCs. In addition,
secreted vesicles also express co-stimulatory molecules. More
efficient T cell activation was obtained with exosomes purified
from mature, rather than immature, DCs, suggesting that
costimulatory molecules present in EVs play indeed a role in the
immune response (Admyre et al., 2003). Such EVs are not only
capable of presenting antigens directly to T cells but are also
able to transfer both the MHC II molecule and the antigen to
naïve DCs thus amplifying the immune response (Thery et al.,
2002). EVs from mature DCs primed with male antigen peptide
enhance male skin graft rejection by female mice (Segura et al.,
2005). In vitro priming of DCs with specific antigens results in the
production of EVs which can induce in vivo humoral responses
against the same antigens (Clayton et al., 2001; Aline et al., 2004;
Qazi et al., 2009), stimulating both T and B cells, leading to both
memory Th1 and immunoglobulin responses (Qazi et al., 2010).
A promoting effect on NK activity was observed in clinical trials
of cancer patients treated with EVs from their own DCs primed
in vitro with their cancer cells (Escudier et al., 2005; Viaud et al.,
2009).
Tumor-derived EVs can also play opposite roles in immune
response, depending on yet poorly identified mechanisms.
Cancer EVs can stimulate the immune response by transferring
tumor antigens to DCs (Wolfers et al., 2001), leading to Ag-
specific T cell activation, in particular of CD8 cytotoxic T
lymphocytes (CTL) clones (Hsu et al., 2003; Utsugi-Kobukai
et al., 2003; Chaput et al., 2004; Escudier et al., 2005). Although
tumor-derived EVs can prime DCs to stimulate the immune
response, they can also behave as immunosuppressive (Poutsiaka
et al., 1985; Clayton et al., 2007) favoring cancer escape from
immune surveillance. Tumor-derived EVs can induce T cell
apoptosis via FasL (Andreola et al., 2002; Huber et al., 2005)
and galectin-9 (Klibi et al., 2009), inhibit IL-2-induced T cell
proliferation (Thery et al., 2002), promote Tregs (Szajnik et al.,
2010), reduce CD8+ T cells proliferation (Wieckowski et al.,
2009) and decrease NK cell cytotoxicity (Ashiru et al., 2010), as
well as induce myeloid supressor cells (Cocucci et al., 2007).
Vesicles secreted by immune cells can also display
immunosuppressive properties. As mentioned above, EVs
secreted by immature DCs can induce tolerogenic, rather than
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effector immune responses (Peche et al., 2003). It was shown
that such EVs promote graft survival (Peche et al., 2003) and
reduce inflammation in animal models of arthritis (Kim et al.,
2005), of inflammatory-bowel disease (Yang et al., 2010) and of
septic shock (Miksa et al., 2006, 2009). Activated T cells secrete
exosomes bearing FasL, which induce apoptosis of neighboring
T cells, suggesting their participation in the regulation of
immune response by a negative feedback mechanism (Monleon
et al., 2001). Interestingly, placenta secretes EVs which seem
to contribute to fetomaternal tolerance (Taylor et al., 2006).
Exosomes in plasma of pregnant women bear FasL and reduce
CD3ζ expression by T cells (Taylor et al., 2006) as well as NKG2D
ligands, reducing the cytotoxicity of NK and CD8+ T cells
(Hedlund et al., 2009).
IMMUNOMODULATORY ROLE OF
MSC-DERIVED EVs
Recent studies indicate that the immune modulatory activity
of MSCs can be at least partially mediated by their ability
to release EVs. The inhibitory effects of MSCs on B-cell
proliferation and differentiation in a CpG-stimulated peripheral
blood mononuclear cell co-culture system could be fully
reproduced by EVs isolated from MSC culture supernatants
in a dose-dependent fashion (Budoni et al., 2013). A dose-
dependent inhibitory activity of MSC-EVs was also observed
for IgM, IgG, and IgA production. Moreover, in the same
coculture system 7-AA-negative and Annexin-positive MSC-
EVs isolated from mesenchymal stromal cells were internalized
in a subset of CD86/CD19 positive cells corresponding to
activated B lymphocytes. The effect of EVs on T cells was
investigated by Mokarizadeh et al. (2012) in a rodent model.
These authors showed that EVs isolated from murine BM-
SCs inhibited the proliferation of both syngenic and allogenic
T lymphocytes. Additionally, they demonstrated that these
microparticles were able to induce apoptosis in activated T
cells. Interestingly, this inhibition was associated with an
increased proportion of regulatory T CD4+-CD25+-FoxP3+
cells. Moreover, an increased secretion of IL-10 and TGFβ1
by cultured splenic cells added with MSC-EVs was observed.
These results suggest that MSC-EVs can induce tolerogenic
signaling. Similar results were observed in human PBMC cultures
treated with human T cell activator CD3/CD28 beads (Del
Fattore et al., 2015a). Stimulation increased the number of
proliferating CD3+ cells as well as of T regulatory cells (Treg).
Co-culture with MSCs inhibited the proliferation of CD3+ cells,
with no significant changes in apoptosis. Addition of MSC-
EVs to PBMCs did not affect proliferation of CD3+ cells, but
induced the apoptosis of CD3+ cells and of the CD4+ sub-
population and increased the proliferation and the apoptosis
of Treg. Moreover, MSC-EV treatment increased the Treg/Teff
ratio and the immunosuppressive cytokine IL-10 concentration
in culture medium. The activity of indoleamine 2,3-dioxygenase
(IDO), an established mediator of MSC immunosuppressive
effects, was increased in supernatants of PBMCs co-cultured
with MSCs, but was not affected by the presence of MSC-EVs.
Interestingly, MSC-EVs express Galectin-1 and PD-L1 (Garin
et al., 2007; Kilpinen et al., 2013) two molecules also expressed
on MSC surface (Kadri et al., 2005; Pedemonte et al., 2007).
Galectin-1, an endogenous leptin, has been shown to induce
apoptosis of activated T cells (Rabinovich et al., 2000) and to
promote the generation of Treg (Blois et al., 2007) PD-L1, a
negative costimulatory molecule for PD-1, also promotes Treg
proliferation and function (Freeman et al., 2000; Chen et al.,
2003). Moreover, MSC-EVs express TGF-alfa, a well-known
inducer of Treg (Chen et al., 2003).
In vitro results are also supported by in vivo observations in
an animal model of inflammatory bowel disease (Del Fattore
et al., 2014) induced by dextran sulfate sodium (DSS). Mice
injected daily with MSC-EVs showed less weight loss, improved
disease activity index and a less severe reduction in colon
length when compared to DSS/vehicle-treated controls. qRT-
PCR analysis performed on RNA extracted from colon tissue
revealed a strong inhibition of the induction of inflammatory
cytokines with respect to untreated animals. Collectively, these
data suggest that EVs isolated from MSCs could reproduce
the immunomodulatory effect of MSCs. Indeed, MSC-EVs are
attracting increasing interest since they might represent a more
convenient therapeutic tool with respect to their cells of origin.
Interestingly, a case of successful treatment with MSC-EVs in
a patient with steroid-resistant GVHD was recently reported
(Kordelas et al., 2014). However, additional work both in vitro
and in vivo is needed in order to better understand both the
potency and the mechanisms of action of this novel potential
immunosuppressive tool.
EV-MEDIATED IMMUNOMODULATION
IN NEUROLOGICAL DISORDERS
The use of EVs for immunomodulation of neurological
disorders is still in its infancy, however, several attempts have
been devised. Genetically modified DCs to equip EVs with
TGF-β1 inhibited the progression of murine experimental
autoimmune encephalomyelitis (EAE; Yu et al., 2013).
Immature DC-derived exosomes ameliorated the progression of
experimental autoimmune myasthenia gravis (Bu et al., 2015).
Exosomes derived from atorvastatin-modified DCs ameliorated
experimental autoimmune myasthenia gravis by up-regulating
the levels of IDO and of Tregs and shifting Th1/Th17 to
Th2 cytokines (Li X.L. et al., 2013, 2016). The mesenchymal
stromal cell-derived EVs rescued traumatic brain injury (TBI)-
induced cognitive impairment in part through reducing of
neuroinflammation (Zhang Y. et al., 2015; Kim et al., 2016).
EVs IN THE BRAIN NEURAL-GLIAL
NETWORKS
In the nervous system EVs are released by many cells including
cortical and hippocampal neurons, glial cells, astrocytes, and
oligodendrocytes and that EVs have significant impact on
communication within the CNS. EVs present in extracellular and
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cerebrospinal fluids transfer protein, lipid and nucleic acid cargo
from one cell to another modifying the target cell phenotype and
function (Agnati et al., 2010). Several lines of evidence reveal
that EVs relay complex messages other than (or even superior
to) those based on direct cell-to-cell contacts or secreted soluble
factors.
In neurons, EVs shed at the synapses are implicated in trans
synaptic communication. They can be retaken by other neurons
suggesting a novel way for inter neuronal communication. The
first evidence of EVs release from neural cells was demonstrated
in vitro using primary culture of embryonic cortical neurons
isolated from rats and mice (Fauré et al., 2006). Additional studies
reported secretion of EVs from fully differentiating cortical
cells, which contained glutamatergic and GABAergic neurons
in long-term culture (Lachenal et al., 2011). In mammalian
cortical neurons EVs are predominantly distributed within
somatodendritic compartment, where they are 50 times more
represented than in axons (von Bartheld and Altick, 2011).
EVs deriving from this compartment may exert alternating
functions at the level of synapses. Indeed in neurons, EVs are
present in both pre- and postsynaptic components. Studies on
trafficking of synaptic AMPA type receptors, which represent the
main mediators of fast synaptic transmission among glutamate
receptors of the CNS showed that neuronal EVs act as stores for
synaptic receptors (Kennedy and Ehlers, 2006). As neuronal EVs
carry AMPA receptor subunits they may play a role in synaptic
plasticity by regulating the AMPA receptors for glutamate
transmission (Chivet et al., 2013). Moreover, EVs can transport
functionally competent GPCRs adding a further level of plasticity
forming the receptors that acquire the ability to respond to its
neurotransmitter ligand (Guescini et al., 2012). It was shown that
increasing cytosolic calcium, incubation with GABA receptor
antagonists or neuron depolarization increased EVs secretion
(Lachenal et al., 2011; Chivet et al., 2012; Pegtel et al., 2014).
In addition to neurons, other cells in the CNS release higher
amount of EVs. Astrocyte-derived EVs are heterogeneous
and their composition depending on the environment.
A large number of transfer compounds such as mitochondria,
mitochondrial DNA, ATP, glutamate transporters, Hsp/Hsc70
and synapsin I involved in neuroprotection, factors modulating
angiogenesis, i.e., FGF2, VEGF, PEDF, and endostatin, as well
as MMPs mediated ECM proteolysis have been identified in
astrocytic EVs (Frühbeis et al., 2013; Agnati and Fuxe, 2014;
Pegtel et al., 2014). The target cells are both astrocytes and
neurons, dependent on the cargo in EVs they may produce, being
involved in neuronal growth and survival, synaptic transmission
regulation or degeneration. Astrocytic EVs can contain excitatory
amino acid transporters that may have special function in volume
transmission by scavenging glutamate in the extracellular fluids,
reducing excitation, and neurodegeneration (Agnati and Fuxe,
2014).
Microglial provide the first line of defense during infection
and brain injury. Upon stimulation reactive microglia release EVs
that transmit inflammatory signals to recipient microglia which
then upregulate the expression of genes enhancing inflammation,
i.e., IL-1β, IL-6, iNOS, cyclooxygenase etc. (Verderio et al., 2012;
Prada et al., 2013). Thus microglial EVs spread inflammatory
reactions throughout the brain. It is of interest that microglia-
derived EVs can interact with neurons and enhance excitatory
transmission modulating synaptic activity (Antonucci et al.,
2012). In addition microglia release EVs with protein content
previously reported in B cell- and DC-derived EVs. Although
MHC class II antigens are visualized in microglial EVs,
their relevance for antigen presentation exhibited by microglia
themselves is still open (Potolicchio et al., 2005).
Oligodendrocytes produce the myelin sheath around axons
thus facilitating impulse conduction. Recent studies suggest that
these trophic functions may depend on the transfer of EVs
from oligodendrocytes to neurons. Indeed, the oligodendrocyte
EVs contain myelin proteins such as PLP, CNP, MAG, and
MOG (Krämer-Albers et al., 2007; Frühbeis et al., 2013).
The secretion of EVs from oligodendrocytes is regulating by
neurotransmitter signaling. Axonally released glutamate activates
EVs release from oligodendrocytes mediated mainly by NMDA
receptors. In addition, oligodendrocyte-derived EVs have been
suggested to negatively regulate myelin synthesis in an autocrine
manner (Bakhti et al., 2011). However, Fruhbeis and colleges
did not observe PLP-positive EVs in myelinating fibers in situ
and postulated that EVs derived from oligodendrocytes are
released into the periaxonal space and thus involve in axon-glia
interaction (Frühbeis et al., 2013). Moreover, oligodendrocyte
EVs improve the metabolic activity of cultured neurons under
cell stress by delivery of supportive biomolecules. This is the
evidence that EVs released from oligodendrocytes participate in
bidirectional neuron-glial integrity.
Extracellular vesicles released by neural cells into brain
parenchyma could be potentially endocytosed by nearby cells.
Then EVs cargos are released into the cytosol of receiving cell
or re-express at the cell surface. Astrocytes, which enwrap a
number of glutamatergic synapses could capture EVs released
at synapses. Back-fusion EVs has been demonstrated to occur
in CNS and could concern their cells of origin. On the other
hand EVs released from particular neural cells can be engulfed
by other type of cells in CNS. EVs secreted by neurons may be
transferred between spines of the same neuron or across synapses
to end up in afferent neurons. Microglial EVs are able to be
internalized by the same cell or by the neighboring microglia in
macro-pinocytic fashion (Chivet et al., 2012). Oligodendrocyte-
derived EVs are usually taken by neurons. This uptake seems
to be selective since astrocytes and oligodendrocytes internalize
oligodendroglial EVs to a minor extent. There is an evidence that
oligodendrocytes also interact with and respond to microglia via
releasing EVs that are taken by recipient cells (Peferoen et al.,
2013; Figure 2).
EV-BASED STRATEGIES FOR
DIAGNOSIS OF CNS DISEASES
Extracellular vesicles are increasingly gaining attention in
diagnostic tools, being used as potential biomarkers for the
detection of early pathological conditions before the onset of
clinical symptoms of the disease. The choice of potential sources
for EVs includes blood, plasma and cerebrospinal fluids. Relative
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 May 2016 | Volume 10 | Article 109
fncel-10-00109 May 12, 2016 Time: 18:40 # 10
Koniusz et al. EV in Physiology and Pathology
FIGURE 2 | The neuronal-glial networks signaling using EVs with potential impact of mesenchymal stem cells (MSC)-derived EVs treatment on
nervous tissue regeneration.
stability of EVs in body fluids and their ability to pass the blood–
brain barrier have suggested to exploit them very easy with
minimally invasive procedure (so called “liquid biopsy”). Finding
and testing such biomarkers in parallel with other diagnostic tools
might be very important in CNS disorders to understand complex
neurological conditions.
The molecular content of EVs namely proteins, nucleic acids,
and lipids reflects the origin and the pathophysiological status
of the releasing cells. Several studies have demonstrated that
EVs isolated from body fluids of neurological patients comprise
molecules implicated in neurodegenerative diseases, metabolic,
infectious diseases, or cancer. The concentration of EVs increases
upon inflammation accompanied different neurological diseases
and it is closely related with disease course (Lee et al., 1993;
Verderio et al., 2012).
Certain EV proteins provided a tool to distinguish a disease-
related condition from a healthy state. For example, amyloid
precursor protein fragments (APP) or tau phosphorylated at
Thr181 are established biomarkers for Alzheimer’s disease,
and phosphorylated tau or α-synuclein are relevant for
Parkinson’s disease (Saman et al., 2012; Yang et al., 2015).
The presence of scrapie form of the prion protein (PrPSC)
in isolated EVs is usually the evidence of Creutzfeld-Jacob
disease (Coleman et al., 2012; Coleman and Hill, 2015). Many
recent reviews addressed different EVs-derived proteins as of
brain tumors diagnosis (Pegtel et al., 2014; Kawikova and
Askenase, 2015; Paschon et al., 2015). These proteins are
usually present on EV surface and could be general cancer
markers, cancer-type markers or tissue-type markers. Plasmatic
levels of cancer-derived EVs were reported to be related to
the tumor size, the metastatic behavior of tumor (calveolin-
1) or their impact on angiogenesis, pro-survival, apoptosis,
immunomodulation, or drug resistance (D’Asti et al., 2012;
Redzic et al., 2014). In particular, the persistence of tumor-
specific exosomes in body fluids such as blood after resection
of tumor on the primary site can indicate the existence of
metastases, which could be located in various organs including
brain and may spur further diagnostics and treatment. The
examination of EVs content in blood samples from control
and glioblastoma patients was performed by Shao et al. (2012).
They created a very innovative system in which isolated
EVs were labeled with magnetic nanoparticles reacting with
specific proteins and then identified by the miniaturized nuclear
magnetic resonance system. This strategy allowed to identify
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with high detection sensitivity glioblastoma-secreted exosomes
and to distinguish them from EVs originating from healthy
individuals.
The disease-specific proteins secreted in EVs or incorporated
into their membrane were found in in vitro research in response
to cells infection by viruses spreading on CNS like human
immunodeficiency virus 1 (etiological cause of Acquired Immune
Deficiency Syndrome), human T-cell leukemia virus-1 (evoking
tropical spastic paresis), herpes simplex virus-1 (inducing herpes
viral encephalitis; Sampey et al., 2014).
Several studies have revealed genetic alterations in RNA
in EVs derived from neurological disorders in comparison
with healthy individuals (Rao et al., 2013; Mundalil Vasu
et al., 2014). Profiling RNA expression patterns could facilitate
presymptomatic disease detection. Recent reports point out
EVs nucleic acids as the biomarkers corresponding to brain
injury, neurodegenerative diseases, neuroinflammation, or brain
tumors. Exosome Diagnostic (Cambridge, MA, USA) filed a
patent reporting a technique to detect neurodegenerative diseases
and brain injury based on the measure of RNA-s (mRNA,
miRNA, siRNA, or shRNA) associated to CSF-derived EVs
(Skog and Russo, 2015). In the reported examples, biomarkers
associated with different neurodegenerative diseases were nucleic
acids corresponding to APP, Aβ42, BACE1, and tau protein
(Urbanelli et al., 2015). The study of Skog et al. (2008) revealed
the presence of oncogenic acids in EVs derived from brain tumors
into CNF. Molecular analysis of oncosomes shed from brain
tumor cells indicates the presence of mRNA coding mutated
genes, non-coding RNA (multiple miRNAs), transcripts for
different oncoproteins or oncogenic DNA sequences. Amongst
the described examples the point mutation in gene coding
epidermal growth factor receptor (EGFRvIII) was found in
EVs isolated from glioblastoma patients (Weller et al., 2014).
Similarly, mRNA for mutated form of IDH1/2 gene and mRNA
for abnormal C-myc gene were observed in EVs circulating
in blood of glioma and medulloblastoma patients, respectively
(Balaj et al., 2011; Chen et al., 2013). Recently, EVs from
glioblastoma and astrocytoma have been shown to carry mtDNA
and dsDNA representing the whole genomic DNA, which can be
used to identify mutations present in tumor cells (Thakur et al.,
2014).
As stated above, EVs are involved not only in physiological
processes but also in CNS diseases carrying specific pathologic
cargo. Over the last decades, besides of using them as biomarkers
of different diseases EVs have been proposed as therapeutic tools
for neurological disorders.
NON-INVASIVE IMAGING OF EVs
Mesenchymal stem cells have the ability to release several pro-
survival trophic and immunomodulatory factors (Abboud et al.,
1991; Aggarwal and Pittenger, 2005; Wilkins et al., 2009; Jitschin
et al., 2013). Because of these beneficial properties, MSCs have
been successfully used in experimental animals to treat several
neurological disorders and to improve graft survival in the CNS
(Srivastava et al., 2016). Human MSCs derived from BM or UCB
were shown to have a strong capacity for exosome secretion
in response to cellular injuries (Baglio et al., 2012; Li T. et al.,
2013) and the pro-survival and immunomodulatory effects of
these cells may be attributable to exosome release. The imaging
of exosomes in vivo may contribute to an understanding of
the regenerative potential of exosomes released from MSCs and
would also represent a significant advancement in translational
exosome science.
The ability to non-invasively track exosomes in vivo using
different imaging modalities is still in its infancy. Because of
their nanometre size, the traditional method of visualization
of exosomes is scanning electron microscopy (SEM; Sharma
et al., 2010; Sokolova et al., 2011). SEM allows particle size
determination, and therefore helping to distinguish between
exosomes and other vesicles. Fluorescence nanoparticle tracking
analysis (NTA) has also been used to determine the exosome
size on the basis of Brownian motion (Dragovic et al., 2011).
Other methods include bright fluorescent labeling of cell-derived
exosomes and high-resolution flow cytometry for quantitative
and qualitative analysis (van der Vlist et al., 2012) and Tunable
Resistive Pulse Sensing analysis, a high resolution technique
that measures the change in electrical resistance in a pore as a
particle passes through it (Coumans et al., 2014). However, these
methods are not ideal for the visualization of in vivo localization
and biodistribution of exosomes. In the last several years, the
development of in vivo imaging techniques has significantly
improved our ability to non-invasively track exosomes. With
these techniques, we can now monitor the distribution of
exosomes at the site of injury or elsewhere in the body.
Exosomes could be visualized by introducing a labeling agent,
and then, imaging the labeling agent as a surrogate for the
exosomes. Depending on the labeling agent, exosomes can be
imaged by optical imaging, magnetic resonance imaging (MRI),
or single-photon emission computed tomography (SPECT).
Lai et al. (2014) used an optical imaging approach to visualize
exosomes. They labeled exosomes with Gaussia luciferase for
non-invasive bioluminescence imaging (BLI). BLI is based on
the emission of photons in reactions catalyzed by luciferase
enzymes. Luciferases emit photons during the oxidation of a
substrate, such as D-luciferin, in the presence of oxygen and
ATP. BLI of immunodeficient, athymic nude mice systemically
injected with exosomes showed a prominent bioluminescence
signal in the spleen (Lai et al., 2014). In another study,
Grange et al. (2014) used small-molecule near-infra red (NIR)
fluorophores to label exosomes and track them for non-
invasive visualization. They used two different exosome labeling
protocols. In the first protocol, MSC-derived exosomes were
directly labeled with Vybrant DiD during an ultracentrifugation
procedure. In the second protocol, exosomes were indirectly
labeled with fluorophores by incubating MSCs with a Vybrant
DiD cell-labeling solution, and then, isolating exosomes from
MSCs by ultracentrifugation. In vitro optical imaging showed
a brighter fluorescence signal in exosomes directly labeled
with DiD compared to exosomes obtained by MSCs that
were previously labeled with DiD. In vivo optical imaging
of mice with acute kidney injury, intravenously injected with
directly or indirectly labeled exosomes, showed an accumulation
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of exosomes, especially in the kidneys (site of injury) of
mice. Directly labeled exosomes showed a higher and brighter
fluorescence compared to indirectly labeled exosomes. This study
showed that both labeling methods were suitable for the in vivo
detection of exosomes (Grange et al., 2014). However, one of
the major limitations of optical imaging is light absorbance from
hemoglobin and multi-layer anatomical barriers that limit the
light emission.
Another method for exosome visualization is MRI. High
spatial resolution and the ability to gather accurate anatomical
information and image deep inside the tissue are some
of the greatest advantages of MRI. Superparamagnetic iron
oxide (SPIO) nanoparticles are MRI contrast agents that are
conventionally used for cell-tracking. SPIOs are based on
magnetite or maghemite cores embedded and stabilized with
a hydrophilic shell. The SPIO core contains several million
iron atoms. These particles create a large dipolar magnetic field
(Hao et al., 2010) and signal spin-spin dephasing due to the
local field inhomogeneity induced in water molecules near the
particles (Rogers et al., 2006). This results in negative contrast
on T2-weighted MRI. Hu et al. (2014) utilized this property
to track exosomes by labeling them with SPIOs. They labeled
mouse B16-F10 melanoma cell-derived exosomes with SPIOs by
using electroporation. These SPIO-labeled exosomes were then
injected into the footpad of C57BL/6 mice. MRI of these mice
showed visually appreciable nodal enhancement and apparent
enlargement 48 h after the injection (Hu et al., 2014). This study
was a proof-of-principle study that demonstrated that exosomes
can be tracked by MRI. One of the major disadvantages of this
method is the possible release of iron particles from exosomes
and their deposition in the tissue. Deposited iron particles could
be scavenged by macrophages and may generate a false-positive
signal on MRI.
The nuclear imaging modality, SPECT, could also be used
to image exosomes. Because of the superior tissue penetration
capability of SPECT, and its more quantitative nature than optical
imaging (Massoud and Gambhir, 2003), the use of SPECT for
exosome imaging presents a better clinical potential. A study by
Hwang et al. (2015) reported a simple method for radiolabelling
of macrophage-derived, exosome-mimetic nanovesicles (ENVs)
with 99mTc-HMPAO (a clinically used tracer) under physiologic
conditions, and monitored the in vivo distribution of 99mTc-
HMPAO-ENVs using SPECT/CT in living mice. SPECT/CT
images exhibited a higher uptake of ENVs in the liver and no
uptake in the brain (Figure 3; Hwang et al., 2015). Although
this technique shows greater promise for investigating the in vivo
behavior of exosomes and is more clinical applicable, the trade-
off between half-life and long-term exposure to ionizing radiation
and a possible transfer of radiometal to surrounding cells could be
a major limitation of using 99mTc-HMPAO for tracking.
THERAPEUTIC POTENTIAL OF
MSC-DERIVED EVs IN CNS DISORDERS
While the use of MSCs in regenerative medicine raised high
expectations in clinical settings, the use of MSC-derived vesicles
released by these cells could have many advantages compared
to a cell-based approach. Therapeutic potential of EVs seems to
be more attractive because it reduces the risk associated with
engraftment of cells, possible immune reactions against cells and
emboli. Moreover, EVs have a unique ability to cross biological
barriers as was shown in glioblastoma patients (Noerholm et al.,
2012; Shao et al., 2012) what is very important for neurological
disease therapy where the compounds that are administered
systemically need to cross blood-brain barrier and blood-CSF
barrier.
Extracellular vesicles may affect cell senescence, proliferation
and cell survival reducing apoptosis resulting from brain
ischemic injury. Besides, as EVs from MSCs were shown to
modulate several signaling pathways, they could be used to
treat neurodegenerative diseases or brain tumors. MSC-derived
EVs have been reported to contribute to tissue repair using
the experimental models of brain injury. Xin et al. (2013a)
showed that systemic administration of EVs generated from bone
marrow-derived MSCs significantly increased axonal density
and synaptophysin-positive area in the ischemic cortex and
striatum of middle carotic artery occlusion (MCAo) rats. BM-
MSC-derived EVs treatment increased also the number of newly
formed doublecortin positive cells (neuroblasts) and improved
functional recovery of stroke rats compared with PBS-treated
controls. The observation of Xin et al. (2013a) that BM-MSCs
exposure to ischemic rat brain extract induced the expression
of miRNA133b in MSC and the previous statement of Yu
et al. (2011) that miRNA 133b was essential for the functional
regeneration of motor neuron axons after spinal cord injury
in zebrafish prompted the authors to check this effect in vitro.
Treatment of primary rat cortical neurons with EVs-derived from
ischemic brain extract-treated MSCs increased the total number
of neurites and their length after 48 h (Xin et al., 2012). Further
studies have demonstrated that BM-MSC-derived EVs transfer
of miRNA133b into rats subjected to MCAo induced neurite
remodeling, increased axonal plasticity and functional outcome
of rats 14 days after stroke onset (Xin et al., 2013b). This effect
has been selectively specific since GTPase RhoA, an miRNA 133b
inhibitor usage did not change neurite morphology. This was the
proof that EVs-mediated secretion of miRNA contributes to the
protective effect of MSCs on stroke.
In addition to the beneficial effect on neurogenesis, EVs
promote angiogenesis post stroke. Rats that received BM-MSC-
EVs demonstrated a significant increase in the percentage
of BrdU/vWF- positive cells in ischemic zone (Xin et al.,
2013b). Cerebral endothelial cell proliferation contributed to
neurovascular remodeling with the ischemic tissue. Therapeutic
application of EVs obtained from human bone marrow derived
mesenchymal stem cells (hBM-MSC) has been also shown in
the experimental model of TBI in rats. Intravenous injection
of secretome from hBM-MSC ameliorated TBI-induced rats by
reducing neuronal cell loss in the injured cortex and promoting
proangiogenic VEGF production resulting in functional outcome
improvement (Chuang et al., 2012). Moreover, rats treated with
EVs derived from BM-MSC of normal and cerebral ischemic
rats had decreased infract volume in comparison to untreated
animals. Similarly, the recovery of neurological functions after
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FIGURE 3 | In vivo SPECT/CT images of 99mTc-HMPAO-ENVs injected in mice. After intravenous injection of 99mTc-HMPAO-ENVs or 99mTc-HMPAO,
SPECT/CT images were acquired at 30 min, 3 h, and 5 h in BALB/c mice. The SPECT/CT imaging showed the significantly intense uptake of 99mTc-HMPAO-ENVs
in the liver and radioactivity in the salivary glands and intestine until 5 h. (Reproduced from Hwang et al., 2015.)
ischemic stroke was observed after application of condition
medium of rat MSC derived from bone marrow, accompanied
with the increase of neuronal progenitor cells surrounding lateral
ventricle in stroke affected hemisphere (Tsai et al., 2014).
Recently, a new therapeutic possibility for using MSC-derived
EVs against Alzheimer Disease was proposed by Katsuda et al.
(2013). The authors have found that human AT-MSCs secrete
nephrilysin (NEP), which is the most important β amyloid (Aβ)–
degrading enzyme in the brain. The functional NEP – bound
exosome derived from hAT-MSC decreased Aβ overexpressed by
neuroblastoma cells in co-culture settings (Katsuda et al., 2013).
Apart from natural EVs, genetically engineered exosomes can
be used as a delivery system for small molecule therapeutics
for treating CNS diseases. EVs are proposed as ideal nucleic
acid transporters. The study of Pusic et al. (2014) exploring the
ability of DC-derived exosomes packed with miRNA showed
a significant increase in myelination observed in hippocampal
slice cultures subjected on oxidative stress. In another study,
exogenous delivery of miR-124a by stereotactic injection of
neuronal cell-derived EVs prevented pathological loss of GLT1
protein, an important glutamate transporter, selectively lost
in amyotrophic lateral sclerosis, in SOD1 G93A mice the
experimental model of ALS (Morel et al., 2013).
The neuro-oncologic application of EVs harnessed with
miRNA has come from the observation that such modified
BM-MSC-derived EVs were incorporated by tumors cells in co-
culture system (Katakowski et al., 2010). Followed by in vivo
studies, intra-tumor injection of endosomes-derived from miR-
146 overexpressing BM-MSC significantly have been shown to
reduce glioma xenograft growth in rat brain (Katakowski et al.,
2013). Not only microRNA but also mRNA and siRNA have
been overexpressed in donor cells and delivered by exosomes.
Exosomes isolated from HEK-293T cells previously transfected
with suicide mRNA triggered tumor cell apoptosis and tumor
regression after their direct injection into schwannoma (nerve
sheat tumor) in an orthotopic mouse model (Mizrak et al., 2013).
EVs isolated from different cell types loaded with siRNA have also
been shown to be successful cargo vehicles for siRNA delivery to
the brain (El Andaloussi et al., 2013). The first in vivo example
of how to exploit EVs carrying siRNA has come from Alvarez-
Erriti studies. Systemic delivery of DC-derived EVs previously
tackled with exogenous si-RNA induced knockdown of BACE1,
a therapeutic target in AD in the mice brain (Alvarez-Erviti et al.,
2011).
It is important to recall that EVs may supress the immune
response. This strategy may provide a novel therapeutic approach
for treating brain inflammatory-related diseases of CNS such
as Parkinson’s disease, Alzheimer disease, multiple sclerosis,
amyotrophic lateral sclerosis, meningitis, brain, spinal cord, and
peripheral nerve injury and brain tumors. The anti-inflammatory
effect of AT-MSC-derived EVs was shown to improve rat sciatic
nerve regeneration after experimental transection (Raisi et al.,
2014). Moreover, genetically modified EVs could deliver different
immunosuppressant substances to modify immune reaction. The
antioxidant curcumin-loaded exosomes isolated from murine
macrophage cell line have been shown to decrease IL-6 and
TNF levels in vitro and in vivo (Sun et al., 2010). In a separate
study BV2 microglial cell line derived exosomes encapsulating
signal transducer and activator of transcription 3 (STAT-3)
inhibitor (JSI-124) were delivered to the brain and selectively
taken up by microglial cells induced apoptosis (Zhuang et al.,
2011).
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A specific application of exosomes released by MSCs was
patented by Beelen et al. (2014). The authors claimed that
exosome preparations derived from neonatal and adult tissue-
derived MSCs were effective for the therapy of inflammation
pre- and post-natally acquired damages of the brain (Beelen
et al., 2014). Another patent disclosed the preparation and use
of exosomes isolated from neural stem cells induced from MSCs
for the treatment of CNS diseases (Tian et al., 2013).
The use of EVs derived from MSCs allows also for avoiding
risk related to the direct deposition of MSCs in the CNS such
as formation of fibrotic masses (Grigoriadis et al., 2011; Snyder,
2011).
CONCLUSION
The field of EVs is maturing with a fast progress in the untangling
of structure and content of EVs. There are also advances in
understanding of biological activities of EVs, in particular in
cancer and in immunology-related diseases, but its role in CNS
disorders also draws a lot of attention, recently. It translated to
the attempts to use EVs as biomarkers of CNS disorders as well
as therapeutic agents. MSs have been shown to be therapeutic in
many neurological disorders despite the lack of homing to the
CNS. Thus, there is growing appreciation of EVs as mediators
of MSC-derived therapeutic effects. MSCs are easy to obtain and
maintain, thus a lot of interest in now paid to replacement of
MSCs by MSC-derived EVs as therapeutic agents. Altogether, the
EVs shed a new light on physiology and pathology, as well as
become an attractive source of therapeutic agents.
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